TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...
A new study by investigators at Dana-Farber Cancer Institute and Harvard Medical School is providing one of the most detailed portraits to date of how myeloproliferative neoplasms (MPNs) evolve from ...
Ultra-low-pass whole genome sequencing (ULP-WGS) of circulating tumor DNA appears to provide important prognostic information regarding patients with large B-cell lymphoma (LBCL), according to ...
In the ovarian cancer cohort, the median time to response was 1.3 months and median duration of response was 8.0 months. Post the September 4, 2025 data cutoff date, four uPRs were confirmed and one ...
The regimen of bexmarilimab and azacitidine (Vidaza) demonstrated a highly promising efficacy profile with a manageable ...
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial We analyzed a cohort ...
Four trials presented at the recent American Society of Clinical Oncology (ASCO) meeting showed promise of new drug combinations or monotherapies in treating chronic lymphocytic leukemia (CLL) and ...
AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific ...
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck,colorectal, gallbladder, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback